60 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28692292	73	Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.	Sichuan University and Collaborative Innovation Center For Biotherapy
28279847	40	Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.	Carna Biosciences
27789138	355	Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.	Abbvie Bioresearch Center
28049589	159	A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.	Sri International
27940419	31	Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.	Comenius University In Bratislava
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
27676471	200	Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.	Cnrs
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
25822739	37	Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.	Ku Leuven
24798019	30	Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors.	Institut De Chimie Des Substances Naturelles
23642479	277	Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.	University of Kansas Specialized Chemistry Center
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
22998443	69	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.	Cnrs
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
22863202	94	Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.	Novartis Institutes For Biomedical Research
20138512	82	Discovery of potent and bioavailable GSK-3beta inhibitors.	Roche Palo Alto
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077425	197	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	Harvard Medical School
17935989	146	Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.	Abbott Laboratories
22056746	53	Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.	Boehringer Ingelheim Pharmaceuticals
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21450467	261	Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).	National Human Genome Research Institute
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19837585	46	Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).	National Human Genome Research Institute
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	Glaxosmithkline
15711537	653	A small molecule-kinase interaction map for clinical kinase inhibitors.	Ambit Biosciences
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
27491711	422	Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.	Merck And
30689953	36	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.	Saarland University
30689946	122	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.	Universit£
31693351	473	Discovery of 4	TBA
30998356	26	Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.	Celgene
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31622099	44	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88	Astrazeneca
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
26509640	234	Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.	Abbvie Bioresearch Center
29985601	64	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.	Seoul National University
29398441	111	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	Astrazeneca
29759799	74	Novel non-ATP competitive small molecules targeting the CK2 ?/? interface.	University of Cambridge
28991472	14	The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.	Celgene
29172502	96	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88	Astrazeneca
21381887	3	Synthesis and biological evaluation of fused oxepinocoumarins as free radicals scavengers.	Aristotle University of Thessaloniki
18055202	98	(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).	Johnson & Johnson Pharmaceutical Research and Development
20020776	56	In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.	Vanderbilt University
19041249	48	Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists.	Nippon Shinyaku